Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
A method of tightening inter-cellular junctions in endothelial or epithelial cells includes exposing the endothelial or epithelial cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of Cadherin or claudin-5 in the endothelial or epithelial cells, the inter-cellular junctions are tightened.
1. A method of treating membrane leakage edema in a living subject by tightening inter-cellular junctions in endothelial or epithelial cells to treat membrane leakage induced edema in vivo in a subject comprising:
administering by subcutaneous injection, intravenous injection, parenteral injection, or intraperitoneal injection an effective amount of an N-terminus norrin truncate that has a polypeptide N-terminus cleavage relative to a native norrin protein of up 40 amino acid residues retaining a cysteine-knot motif of the native norrin and capable of binding to the endothelial or epithelial cells, or a norrin mutant having at least 85% amino acid identity to SEQ ID NO. 1 and retaining a cysteine-knot motif of the native norrin and capable of binding to the endothelial or epithelial cells defining one of: a blood vessel, a lymphatic capillary, or a blood-intestinal barrier; and
allowing sufficient time for said N-terminus norrin truncate or said norrin mutant to selectively up-regulate gene expression of Cadherin and claudin-5 in the endothelial or epithelial cells to tighten the inter-cellular junctions of the tissue for prevention of vascular leakage or repair of the vascular leakage to treat the membrane leakage induced edema.
2. The method of claim 1 , wherein said subject is human.
3. The method of claim 1 , wherein said subject is one of: cow, horse, sheep, pig, goat, chicken, cat, dog, mouse, guinea pig, hamster, rabbit, or rat.
4. The method of claim 1 , further comprising diagnosing edema associated with fluid leakage from a compromised cellular junction in the endothelial or epithelial cells prior to the administering step.
5. The method of claim 1 wherein the tissue is experiencing edema prior to the administering step.
6. The method of claim 1 , wherein said N-terminus norrin truncate consists of: a polypeptide of SEQ ID. NO. 2.
7. The method of claim 1 , wherein said N-terminus norrin truncate or norrin mutant is selected from the group consisting of SEQ ID. NO. 3, 5, 6, 7, 8, 9, 10, 11, 14, and 16.
8. The method of claim 1 , wherein said N-terminus norrin truncate or norrin mutant is selected from the group consisting of SEQ ID. NO. 12, 13, 14, 15, 17, 18, 19, 20, and 21.
9. The method of claim 1 , wherein said N-terminus norrin truncate or said norrin mutant is recombinant.